SS18 and synovial sarcoma: Notably, the sole expression of SS18-SSX1/SSX2 is sufficient to drive SS genesis in a mouse model, demonstrating the oncogenic capacity of t(X;18)(p11.2;q11.2) fusion products [7–10].